Zynerba’s Stock on a High as Cannabis-Based Drug Succeeds in Trial

By:
Zynerba's Stock on a High as Cannabis-Based Drug Succeeds in Trial

Pixabay / geralt / CC0 Public Domain

Zynerba Pharmaceuticals Inc said on Thursday its cannabis-based gel met the main goal in a mid-stage study of patients with Fragile X syndrome, a genetic disorder that causes learning disabilities in adolescents and children.

The U.S. drug developer’s shares, which are down 60 percent since the beginning of the year, climbed 71 percent in premarket trading to $10.60.

Zynerba’s drug achieved the main goal in a mid-stage study of adolescents and children with Fragile X syndrome.

View Original Article Here

Repost is the designation for articles collected from the Internet whose content may interest our readers. These articles are not written by our staff and they do not necessarily reflect our views.

Related posts

Top